LLY · 8-K · 20260805PR000077

Products and Technology - Pipeline

ELI LILLY & Co · 2026-08-05 · Importance 34 · Surprise 42

Lilly reported regulatory and clinical progress across multiple therapeutic areas. Ebglyss received U.S. FDA approval for one maintenance dose every eight weeks in moderate-to-severe atopic dermatitis, while Jaypirca received European Commission approval as monotherapy for chronic lymphocytic leukemia across all lines of therapy. VERVE-102 reduced PCSK9 by up to 88% and LDL-C by up to 62% after a single dose, supporting its potential as a one-time hypercholesterolemia treatment. Retevmo demonstrated an 83% reduction in the risk of recurrence or death as adjuvant therapy for early-stage RET fusion-positive lung cancer.